Amtas-5

Quick links to important sections

Amtas-5

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amtas-5

Quick Facts

Property Description
Active ingredient Amlodipine besylate
Form Tablet (Oral Route)
Pharmacological class Calcium Channel Blocker (Dihydropyridine)
General Purpose Manage blood pressure and angina
Origin Synthetic compound

What Type of Medicine is Amtas-5?

Amtas-5 is a specific trade name for a synthetic, single-ingredient prescription medication containing the active compound Amlodipine besylate. It is officially classified as a Calcium Channel Blocker (CCB), specifically falling within the dihydropyridine subclass of antihypertensive agents. This classification indicates the drug's primary function: regulating the way calcium moves into the cells of the arteries. Amlodipine is recognized globally for its safety and effectiveness; it is listed on the Model List of Essential Medicines.

Composition and General Purpose

The composition of Amtas-5 focuses entirely on Amlodipine as the therapeutic agent, delivered in an easy-to-use oral tablet form, with the 5 mg strength being a common dosage unit. The general purpose of taking this medication is tied directly to its relaxing effect on the arteries. Amlodipine is clinically recognized for managing systemic high blood pressure (hypertension) and relieving symptoms of chronic stable angina, or heart-related chest pain. This essential function means the medicine provides a proven way to improve blood flow and reduce the mechanical strain on the heart muscle.

The Principle Behind Calcium Channel Blockers

As a CCB, Amtas-5 primarily acts as a peripheral arterial vasodilator. It works by preventing the influx of calcium ions into the muscle cells that line your arteries. This action prevents the muscles from contracting, which causes the arteries to relax and widen (vasodilation). This effect reduces the resistance the heart must pump against, thereby lowering blood pressure. Amlodipine's action is selective for the peripheral vasculature, which is a key characteristic of its therapeutic profile.

Regulatory References

  1. NIH, StatPearls

What side effects are possible with Amtas-5?

The safety profile of Amtas-5 (amlodipine) is defined by categories of adverse reactions documented in official regulatory sources, organized by frequency and System-Organ Class (SOC). Adverse events are classified using standard frequency categories, such as Common (occurring in 1 to 10 out of 100 patients) and Very Rare (occurring in less than 1 out of 10,000 patients).

Adverse Reaction Scope

Classification System-Organ Class Examples
Very Common (ge 1/10) Oedema (swelling, particularly of the ankles)
Common (ge 1/100 to < 1/10) Nervous System (Headache, Dizziness, Somnolence); Vascular (Flushing); Cardiac (Palpitations); Gastrointestinal (Nausea, Abdominal Pain)

Serious Adverse Reactions and Safety Constraints

Very Rare reactions classified as serious include cardiovascular events such as Myocardial Infarction or Arrhythmia, severe decreases in blood pressure (Hypotension), and reactions involving the liver (Hepatitis, Pancreatitis), or severe skin manifestations like Angioedema or Exfoliative Dermatitis.

Safety documentation notes that oedema is a dose-related adverse reaction, with incidence increasing as the administered dose is increased. Furthermore, effects like headache and dizziness are reported to be more frequent at the beginning of treatment. Caution is required in patients with conditions like Severe Aortic Stenosis or congestive heart failure. For patients with Hepatic Impairment, reduced drug clearance is documented, requiring slow dose titration as specified in official labeling.

This structure ensures that the full range of potential risks, from common, dose-related events to rare, clinically serious reactions, is objectively communicated.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Amtas-5 (amlodipine) overdose focuses on severe, immediate cardiovascular compromise. The primary documented manifestation is excessive peripheral vasodilation, leading directly to marked and prolonged systemic hypotension (severely low blood pressure). This physiological outcome may present with reflex tachycardia, dizziness, and fainting. Overdose carries the risk of life-threatening events, including shock (with fatal outcomes reported) and the potential for non-cardiogenic pulmonary edema.

Due to these severe manifestations, official guidance mandates that individuals seek immediate medical attention. Emergency services must be contacted if the affected person collapses, has trouble breathing, or has a seizure. Management is defined by the need for symptomatic and supportive treatment; no specific antidote is known for amlodipine. Management protocols require active cardiovascular support, including frequent blood pressure monitoring.

Procedures such as gastric lavage and administration of activated charcoal may be considered if ingestion was recent. Regulatory documentation also notes that patients with hepatic impairment may experience prolonged recovery due to delayed drug clearance.

Therapeutic Uses of Amtas-5

What Amtas-5 Treats: Main Uses and Benefits

Amtas-5 (containing the active substance amlodipine) is commonly used across conditions presenting with acute episodes that create noticeable functional strain. It is applied across domains where additional symptomatic support is needed, assisting with conditions characterized by periods of heightened symptoms.

This medication is indicated for the treatment of hypertension and Coronary Artery Disease (CAD). In clinical settings that involve acute or unstable symptom patterns, Amtas-5 is relevant for easing symptoms related to chronic stable angina and vasospastic angina, commonly used to help with symptoms that interfere with daily comfort.

Amtas-5 may assist with maintaining functional stability by easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods. This supportive relief generally helps patients cope more steadily with symptom fluctuations.

“This supportive assistance is commonly used across conditions presenting with acute episodes.”


Relevant for: Easing Symptoms Related to Physical Discomfort

Regulatory References

  1. NIH DailyMed label for Amlodipine Besylate

Eligibility and Restrictions for Use

Amtas-5 (amlodipine) eligibility is strictly defined by regulatory bodies based on absolute prohibition, age, and existing patient conditions. The medicine is strictly prohibited for use in patients with known hypersensitivity to amlodipine, any dihydropyridine derivatives, or its excipients. It is also contraindicated in individuals experiencing severe hypotension or shock, including cardiogenic shock.

Population Status Condition or Age Group
Established Use Adults; Children 6 to 17 years (for hypertension).
Use Not Established Pediatric patients under 6 years of age.
Restricted Use Severe hepatic impairment; Elderly/Small, fragile patients.

Eligibility for adults is established, while use in children under 6 years is officially not established due to insufficient data. Caution is specifically required for patients with severe hepatic impairment, as well as those with severe obstructive coronary artery disease or severe aortic stenosis, due to labeled warnings. Use in renal impairment is generally allowed, as it does not significantly influence the drug's action. The use of Amtas-5 during pregnancy is permitted only when the potential benefit outweighs the potential risk. Use during lactation is generally not recommended by regulatory sources.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Amtas-5 (Amlodipine) outlines specific pharmacokinetic and pharmacodynamic interactions documented in governmental prescribing information.

Amlodipine exposure is significantly influenced by CYP3A4-mediated metabolism. Co-administration with strong or moderate CYP3A4 inhibitors (including certain antifungals, macrolides, or Diltiazem) is documented to increase Amlodipine plasma concentrations, which may result in an increased risk of hypotension. Conversely, CYP3A4 inducers (such as Rifampicin) may decrease plasma concentrations, potentially reducing the drug's effect.

Interaction-related restrictions exist for co-administered drugs: Amlodipine's weak inhibitory properties increase the exposure of Simvastatin, leading to the requirement that the Simvastatin dose must not exceed 20 mg daily. Caution is also noted for immunosuppressants, as co-administration may increase the plasma levels of both Cyclosporine and Tacrolimus.

Regarding other substances, combining Amtas-5 with other antihypertensive agents results in an additive blood pressure lowering effect. The use of Grapefruit or Grapefruit juice is not recommended as it may increase Amlodipine bioavailability and enhance the hypotensive effect. This interaction risk is officially noted to be heightened in patients with severe hepatic impairment due to reduced clearance.

Mechanism of Action

Direct Molecular Blockade of Calcium Channels

The core mechanism begins with Amtas-5 (Amlodipine) acting as a selective inhibitor of the L-type Voltage-Gated Calcium Channels (CaV 1.2). These channels are located primarily on the membrane of vascular smooth muscle cells. By binding to these channels, the drug prevents the necessary influx of calcium ions (Ca^2+) from the extracellular space into the cell cytoplasm, thereby directly interfering with the signal required for muscle contraction.

Modulating Excitation-Contraction Coupling

This inhibition of Ca^2+ entry immediately disrupts the Excitation-Contraction (EC) Coupling pathway within arterial smooth muscle. Because the muscle cell cannot accumulate the calcium ions required to activate its contractile proteins, the muscle fibers remain relaxed. This mechanistic cascade, moving from ion blockade to cellular relaxation, results in widespread arterial vasodilation (widening of the blood vessels) throughout the peripheral and coronary circulatory systems.

Reduction of Systemic Vascular Resistance

The resulting vasodilation acts as the primary physiological consequence, leading to a reduction in the Systemic Vascular Resistance (SVR). This lessens the mechanical load, or afterload, that the heart must pump against. Furthermore, the mechanistic selectivity for vascular smooth muscle contributes to the effect on resistance. The mechanistic selectivity restricts direct influence on the heart's electrical conduction or contractility.

Dosage and Administration Information

How to use Amtas-5: Official Administration Guidelines

Amtas-5 (amlodipine) is a prescription medicine for oral administration only, taken as a tablet by mouth. It is used as a long-term, once-daily treatment.


Standard Dosing and Schedule

The standard adult starting dose for both hypertension and angina is 5 mg once daily. The typical adult maintenance dose ranges from 5 mg up to the maximum recommended daily dose of 10 mg.

Instruction Detail
Route of Administration Oral (by mouth)
Dosing Frequency Once daily
Meal Relation Can be taken without regard to meals (with or without food), as absorption is not significantly affected.
Dose Titration Any increase in dose should be made gradually, typically after 7 to 14 days or longer, to allow the body to reach stable drug levels before adjusting the regimen.

Usage Rules for Specific Populations

For certain patient groups, a lower initial dose is recommended to ensure cautious initiation of the regimen:

  • Older Adults: A reduced starting dose, such as 2.5 mg once daily, may be considered.
  • Hepatic Impairment: A starting dose of 2.5 mg once daily is recommended due to the drug's metabolism and reduced clearance in patients with liver problems.
  • Renal Impairment: No initial dose adjustment is generally required, as renal function does not significantly impact the drug's overall clearance.

Missed Dose Instructions

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Patients are instructed not to take two doses to compensate for the missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amtas-5 (Amlodipine)

The clinical evaluation of amlodipine, the active ingredient in Amtas-5, is based on data from official sources, including large, randomized controlled trials (RCTs), comparative studies, and long-term observational research. The evidence primarily describes research exploring amlodipine in patients diagnosed with high blood pressure, chronic stable angina, and vasospastic angina.


Evidence for Use in High Blood Pressure (Hypertension)

Research examining high blood pressure includes numerous double-blind, placebo-controlled RCTs that research examined in adult populations. These studies explored measuring changes in systolic and diastolic blood pressure readings. Long-term studies monitored the frequency of major cardiovascular events, such as strokes, heart attacks, and all-cause mortality. The findings describe patterns observed in these studies, where amlodipine-based regimens were associated with a difference in the observed frequency of stroke and heart attack compared to other treatment regimens examined in the research.


Evidence for Use in Angina and Coronary Artery Disease (CAD)

Amlodipine was evaluated in controlled trials used in research exploring short-term or episodic symptom patterns for patients with angina. Studies monitored event rates related to the heart, such as the frequency of surgical revascularization procedures or hospitalization due to acute angina episodes. The studies report how patient-reported symptoms evolved in the observed populations, noting a pattern that differed from the pattern observed in the placebo group.

In patients with documented Coronary Artery Disease (CAD), long-term studies monitored a composite of major cardiovascular outcomes. Research findings were mixed regarding the study’s specific goal of measuring whether there was a change in the anatomical progression of arterial plaque within the coronary arteries itself.


Summary of Evidence Gaps and Areas of Uncertainty

While extensive research has explored amlodipine, certain areas require more clarification. Research findings were mixed in some trials regarding the association between amlodipine-based regimens and the rate of heart failure events. Furthermore, there is limited information for long-term outcomes in children under 6 years of age or specific, less-common comorbid conditions. Study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Amtas-5 (FAQ)


Q: Is it common to feel tired or dizzy when starting Amtas-5?

Regulatory documents indicate that dizziness and somnolence (sleepiness) are classified as common side effects. Fatigue is also a reported adverse reaction. These effects are often reported more frequently during the initial period of treatment as the body adjusts to the medicine.

Q: Can Amtas-5 cause problems with sleep?

Official product information lists somnolence (drowsiness) as a common side effect. Less frequently, insomnia (difficulty sleeping) is also noted as an uncommon adverse reaction in some regulatory summaries.

Q: What types of foods or drinks should people using Amtas-5 avoid?

Official labeling advises against consuming grapefruit or grapefruit juice while taking Amtas-5. This is because grapefruit may increase the concentration of the drug in the blood, which could enhance its blood pressure-lowering effect. No other common foods or drinks are typically restricted by regulatory sources.

Q: Can Amtas-5 affect my ability to drive or operate machinery?

Because Amtas-5 can cause side effects like dizziness, headache, or fatigue, it may have an influence on a person's ability to drive or operate complex machinery. Official labeling suggests caution may be necessary, particularly when beginning treatment or when the dosage is changed.

Q: Is Amtas-5 generally considered safe for older adults?

Regulatory documents state that older or fragile patients may require a lower initial starting dose. This cautious approach is used to ensure slow initiation and adjustment based on the body's response, as clearance of the drug may be reduced in this population.

Q: How does Amtas-5 affect my heart rate?

While the drug is primarily designed to act on blood vessels, official information lists palpitations (being aware of your heartbeat) as a common side effect. Changes to heart rate, such as a fast rate (tachycardia) or a slow rate (bradycardia), are listed as less frequent adverse reactions.

Q: Is there any risk of Amtas-5 causing issues with kidney or liver function?

Caution is specifically noted for the liver, as a reduced starting dose is required for patients with severe liver impairment. Serious liver reactions, such as hepatitis, are classified as very rare. No initial dose adjustment is generally required based on regulatory guidance regarding kidney function.

Q: What should I do if I notice swelling in my ankles or feet after starting Amtas-5?

Swelling, particularly in the ankles or feet (oedema), is noted as a very common side effect of Amtas-5. Regulatory data also show this side effect is often dose-related, meaning it is more likely to occur at higher dosages. This type of swelling is a documented effect.

Q: Is Amtas-5 available in different strengths, and what are they used for?

Amtas-5 is generally available in 2.5 mg, 5 mg, and 10 mg tablet strengths. The 5 mg dose is often used as a starting dose for many patients, with doses up to the maximum recommended 10 mg being used for long-term maintenance treatment.

Q: Are there reports of Amtas-5 causing skin rashes?

General skin rash is listed as a common adverse reaction in some regulatory profiles. Very rare, but serious, skin reactions such as Erythema Multiforme are also noted in official safety documentation.

Q: Does Amtas-5 need to be taken at the same time every day?

Amtas-5 is designed as a once-daily medicine. The active ingredient has a long elimination half-life, meaning it stays in the body for a considerable time to provide 24-hour control. A consistent daily schedule supports the maintenance of steady drug levels.

Q: Why is Amtas-5 sometimes prescribed alongside another blood pressure medicine?

Official product information states that Amtas-5 may be used in combination with other blood pressure medicines. This approach is sometimes necessary because combining agents from different classes can result in an additive blood pressure-lowering effect, which helps achieve the desired treatment goals.

Q: Can Amtas-5 cause a temporary drop in blood pressure when standing up?

The mechanism of Amtas-5 involves vasodilation, which lowers blood pressure, and dizziness is a common side effect. While a specific drop in blood pressure when standing is not explicitly called out, the potential for dizziness and symptomatic hypotension (low blood pressure) is noted in regulatory documents.

Q: What are the official warnings associated with Amtas-5?

Specific warnings from regulatory bodies include the potential for symptomatic hypotension (a significant drop in blood pressure), particularly in patients with pre-existing heart conditions like severe aortic stenosis. There is also a warning about the possibility of worsening angina or myocardial infarction upon starting or increasing the dose.

Q: Why do official documents mention specific patient populations who should use caution with Amtas-5?

Caution is advised for specific groups, such as the elderly and those with hepatic impairment (liver problems). This is primarily because regulatory information suggests these patients may have reduced clearance of the drug, increasing the risk of accumulation and side effects.

Q: Is Amtas-5 a common drug, and how many people use it?

The active ingredient in Amtas-5 is listed on the World Health Organization's (WHO) Model List of Essential Medicines. This indicates that it is widely recognized by global health authorities as one of the most important and effective medicines necessary in a basic health system.

Q: How quickly does Amtas-5 usually start working after the first dose?

Clinical pharmacology data indicate that after the first dose, the blood pressure-lowering effect is described as beginning gradually. This effect is typically observed starting anywhere from 4 to 8 hours after the medicine is taken.

Q: What is the typical timeframe for seeing the full effects of Amtas-5?

Because the drug's effect is gradual, dose adjustments are usually made no sooner than 7 to 14 days apart. This waiting period allows the body to reach stable plasma concentration levels, which is the point when the full therapeutic effect can be properly assessed.

Q: Can I stop taking Amtas-5 once my condition seems better?

Regulatory guidance confirms that Amtas-5 is used for long-term management of chronic conditions like high blood pressure and angina. Any change to the regimen requires assessment by a healthcare provider.

Q: Is Amtas-5 known to cause weight gain or loss?

Regulatory safety documents list both weight increase and weight decrease as uncommon adverse reactions. These effects are not typically seen as a common side effect of the medicine.

Q: Does Amtas-5 interact with common over-the-counter pain relievers?

Clinical studies have examined the use of amlodipine alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and have not reported a readily apparent clinically significant interaction. No specific, routine interaction with common pain relievers is noted in official documentation.

Q: Is it safe to drink alcohol while taking Amtas-5?

Official guidance suggests that alcohol may enhance the blood pressure-lowering effects of Amtas-5. This combination is noted in official documentation as requiring caution because it can increase the risk of side effects like dizziness.

Q: Are there any herbal supplements that should not be taken with Amtas-5?

Regulatory information specifically addresses the herbal supplement St. John's wort, which is known to influence drug metabolism. Use of St. John's wort may potentially reduce the concentration of Amtas-5 in the blood, possibly lowering its effect.

Q: Can Amtas-5 be used by people who have diabetes?

Patients with pre-existing conditions, including diabetes, were included in the large-scale cardiovascular outcome trials for amlodipine. This indicates a recognized and studied role for the drug in this patient population.

Q: Does Amtas-5 cause people to develop a cough?

Cough is listed as an uncommon adverse reaction in the regulatory documents, under the category of respiratory disorders.

Q: Can Amtas-5 affect a person's mood or cause anxiety?

Official product information notes that mood alteration (including depression and anxiety) is listed as an uncommon adverse reaction associated with the medication.

Q: How long does the active ingredient of Amtas-5 stay in the body?

The active ingredient has a long elimination half-life, ranging from 30 to 50 hours. This property supports the drug's once-daily dosing regimen.

Q: Is the brand name version of Amtas-5 better than the generic?

In many countries, generic versions of medicine must demonstrate bioequivalence to the original brand name product. This means they are required to contain the same active ingredient and meet bioequivalence standards.

Q: Does Amtas-5 change how my body uses salt?

While not a common side effect, hyponatremia (abnormally low sodium levels in the blood) has been reported in post-marketing case reports as a possible electrolyte disturbance associated with the drug.

Q: Are there common reasons why a doctor might decide to stop Amtas-5 treatment?

Data from clinical trials indicate that the most common reason for study participants to stop taking the medicine due to side effects was peripheral oedema (swelling). Other common reasons included headache and dizziness.

Q: Does taking Amtas-5 mean I can stop lifestyle changes like diet and exercise?

Regulatory-context documents describe medicines like Amtas-5 as being used as one component of a comprehensive strategy for managing chronic conditions. This strategy typically includes recommended non-drug interventions, such as changes to diet and regular exercise.

Q: Does Amtas-5 affect blood sugar levels?

Hyperglycemia (an increase in blood sugar) is listed as an uncommon adverse reaction associated with the medication.

How should Amtas-5 be stored and disposed of?

How to Store and Dispose of Amtas-5 (Amlodipine Besylate)

Amtas-5 must be stored and disposed of according to official regulatory labeling to ensure stability and safety. The medication requires storage at controlled room temperature, specifically between 20^circC and 25^circC (68^circF and 77^circF), with minimal temperature fluctuation. Tablets must be protected from light and moisture, requiring storage in a tight, light-resistant container. For household safety, Amtas-5 must always be kept out of the reach of children.

Disposal

To dispose of unused or expired Amtas-5, utilize an authorized drug take-back program. If a take-back option is unavailable, regulatory guidelines advise mixing the tablets with an undesirable substance, sealing the mixture in a container, and discarding it in the household trash. The medication should not be released into wastewater or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Amtas-5 found in:

A-Z Index: